cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Nektar Therapeutics
12 own
14 watching
Current Price
$0.96
$-0.07
(-6.67%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
235.62M
52-Week High
52-Week High
1.93000
52-Week Low
52-Week Low
0.47999999
Average Volume
Average Volume
1.8M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
9.86
iconMarket Capitalization235.62M
icon52-Week High1.93000
icon52-Week Low0.47999999
iconAverage Volume1.8M
iconDividend Yield--
iconP/E Ratio9.86
What does the Nektar Therapeutics do?
Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. The company offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A. Its drug candidates in clinical development stage comprises BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-214 that is in Phase 1/2 stage to treat cancer; NKTR-181 that is in Phase III clinical trial for treating chronic pain; and NKTR-358 to treat autoimmune diseases. The company's drug candidates in clinical development stage also include ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as completed Phase II clinical trial stage for refractory ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat refractory solid tumor cancers, which has completed Phase I clinical trial. In addition, it holds license, manufacturing, and supply agreements with Ophthotech Corporation for Fovista; and UCB Pharma for dapirolizumab pegol. Further, the company holds a range of license, manufacturing, and supply agreements with other biotechnology and pharmaceutical companies, including Amgen Inc.; Allergan, Inc.; Merck & Co., Inc.; Pfizer, Inc.; and F. Hoffmann-La Roche Ltd (Roche). Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.
Read More
How much money does Nektar Therapeutics make?
News & Events about Nektar Therapeutics.
PR Newswire
1 year ago
Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank PR Newswire SAN FRANCISCO, March 11, 2023 SAN...
Business Wire
1 year ago
Glancy Prongay & Murray LLP (GPM) announces its investigation of Nektar Therapeutics (Nasdaq: NKTR) concerning the Company and its directors and officers possible violations of state laws. If you own Nektar Therapeutics stock, would like to learn more about these claims, or have any...
PR Newswire
2years ago
Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA PR Newswire SAN...
Globe Newswire
2years ago
NEW YORK, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ: NKTR) breached their fiduciary duties to shareholders. The investigation concerns potential self-...
PR Newswire
2years ago
Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting PR Newswire SAN FRANCISCO, Dec. 12, 2022 -- Unveils Trial Design for NektarPhase 2/3 Study...
Frequently Asked Questions
Frequently Asked Questions
What is Nektar Therapeutics share price today?
plus_minus_icon
Can Indians buy Nektar Therapeutics shares?
plus_minus_icon
How can I buy Nektar Therapeutics shares from India?
plus_minus_icon
Can Fractional shares of Nektar Therapeutics be purchased?
plus_minus_icon
What are the documents required to start investing in Nektar Therapeutics stocks?
plus_minus_icon
What is today’s traded volume of Nektar Therapeutics?
plus_minus_icon
What is today’s market capitalisation of Nektar Therapeutics?
plus_minus_icon
What is the 52-Week High and Low Range of Nektar Therapeutics?
plus_minus_icon
What percentage is Nektar Therapeutics down from its 52-Week High?
plus_minus_icon
What percentage is Nektar Therapeutics up from its 52-Week Low?
plus_minus_icon
Current Price
$0.96
$-0.07
(-6.67%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Phibro Animal Health Corp
Phibro Animal Health Corp
$20.25
$0.20 (1.00 %)
Omeros Corporation
Omeros Corporation
$8.78
$-0.06 (-0.68 %)
Akebia Therapeutics Inc
Akebia Therapeutics Inc
$1.88
$0.13 (7.14 %)
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc.
$4.54
$-0.07 (-1.41 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Phibro Animal Health Corp
Phibro Animal Health Corp
$20.25
$0.20 (1.00 %)
Omeros Corporation
Omeros Corporation
$8.78
$-0.06 (-0.68 %)
Akebia Therapeutics Inc
Akebia Therapeutics Inc
$1.88
$0.13 (7.14 %)
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc.
$4.54
$-0.07 (-1.41 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00